Literature DB >> 31975799

Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression.

Boadie W Dunlop1.   

Abstract

Combination treatment with psychotherapy and antidepressant medication can be provided from the initiation of treatment, sequentially after nonremission with a single-modality treatment or sequentially after remission to buttress the patient's recovery to prevent recurrence. Combination treatment from the initiation of care is best reserved for patients with high depression severity. Sequential addition of treatments, particularly psychotherapy after nonremission to antidepressant medication, is the best supported method of combination, improving remission rates and reducing relapse and recurrence in the long term. However, uncertainty persists around the optimal form of psychotherapy to combine with antidepressant medication for maximizing long-term gains. Better outcomes from combination treatment have been strongest in clinical trials that limited pharmacotherapy to a single antidepressant; benefits of combination treatment have been substantially smaller in trials that allowed flexible use of multiple antidepressant classes. Patients with recurrent major depressive disorder who benefit from combination treatment have better long-term outcomes if an active treatment component is maintained during recovery.
Copyright © by the American Psychiatric Association.

Entities:  

Year:  2016        PMID: 31975799      PMCID: PMC6519650          DOI: 10.1176/appi.focus.20150042

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  7 in total

1.  Combining active ingredients to treat depression in the wake of COVID-19.

Authors:  Melanie A Abas
Journal:  Lancet Psychiatry       Date:  2021-12-08       Impact factor: 27.083

2.  Prenatal Venlafaxine Exposure-Induced Neurocytoarchitectural and Neuroapoptotic Degeneration in Striatum and Hippocampus of Developing Fetal Brain, Manifesting Long-term Neurocognitive Impairments in Rat Offspring.

Authors:  K P Singh; Prashant Sharma; Manish Singh
Journal:  Neurotox Res       Date:  2022-07-12       Impact factor: 3.978

3.  A Systematic Review and Individual Patient Data Network Analysis of the Residual Symptom Structure Following Cognitive-Behavioral Therapy and Escitalopram, Mirtazapine and Venlafaxine for Depression.

Authors:  Aoife Whiston; Amy Lennon; Catherine Brown; Chloe Looney; Eve Larkin; Laurie O'Sullivan; Nurcan Sik; Maria Semkovska
Journal:  Front Psychiatry       Date:  2022-02-01       Impact factor: 4.157

4.  Toward Synergies of Ketamine and Psychotherapy.

Authors:  David S Mathai; Victoria Mora; Albert Garcia-Romeu
Journal:  Front Psychol       Date:  2022-03-25

Review 5.  A Southeast Asian expert consensus on the management of major depressive disorder with suicidal behavior in adults under 65 years of age.

Authors:  Kok Yoon Chee; Nalini Muhdi; Nor Hayati Ali; Nurmiati Amir; Carmina Bernardo; Lai Fong Chan; Roger Ho; Pichai Ittasakul; Patanon Kwansanit; Melissa Paulita Mariano; Yee Ming Mok; Duy Tam Tran; Thi Bich Huyen Trinh
Journal:  BMC Psychiatry       Date:  2022-07-21       Impact factor: 4.144

Review 6.  Trends in big data analyses by multicenter collaborative translational research in psychiatry.

Authors:  Toshiaki Onitsuka; Yoji Hirano; Kiyotaka Nemoto; Naoki Hashimoto; Itaru Kushima; Daisuke Koshiyama; Michihiko Koeda; Tsutomu Takahashi; Yoshihiro Noda; Junya Matsumoto; Kenichiro Miura; Takanobu Nakazawa; Takatoshi Hikida; Kiyoto Kasai; Norio Ozaki; Ryota Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2022-01       Impact factor: 12.145

Review 7.  Meta-Analysis of Positive Psychology Interventions on the Treatment of Depression.

Authors:  Shannon Pan; Kiran Ali; Chanaka Kahathuduwa; Regina Baronia; Yasin Ibrahim
Journal:  Cureus       Date:  2022-02-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.